Fondriest Sara A, Gowdy John M, Goyal Manish, Sheridan Katherine C, Wasdahl Daniel A
Radiol Case Rep. 2015 Dec 3;10(1):962. doi: 10.2484/rcr.v10i1.962. eCollection 2015.
A 51-year-old Caucasian female presenting with renal-cell cancer and cutaneous leiomyomas was later diagnosed with Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome. HLRCC is an autosomal dominant condition caused by a mutation in the fumarate hydratase gene, which encodes for an enzyme in the citric acid cycle. This syndrome has been reported in over 100 families throughout the world, the majority of whom are of Eastern European descent. Those with this syndrome have a significantly increased risk of developing renal-cell carcinoma, cutaneous leiomyomas, and uterine leiomyomas, and a smaller chance of developing uterine leiomyosarcomas. This syndrome has a relatively poor prognosis, with tumor metastasis occurring in approximately 50% of patients. However, more aggressive prophylactic measures and recent studies have shown potential to improve patient prognosis.
一名51岁患有肾细胞癌和皮肤平滑肌瘤的白种女性后来被诊断为遗传性平滑肌瘤病和肾细胞癌(HLRCC)综合征。HLRCC是一种常染色体显性疾病,由延胡索酸水合酶基因突变引起,该基因编码柠檬酸循环中的一种酶。全世界已有100多个家庭报告了这种综合征,其中大多数是东欧血统。患有这种综合征的人患肾细胞癌、皮肤平滑肌瘤和子宫平滑肌瘤的风险显著增加,而患子宫平滑肌肉瘤的几率较小。这种综合征的预后相对较差,约50%的患者会发生肿瘤转移。然而,更积极的预防措施和最近的研究表明有可能改善患者的预后。